Raludotatug deruxtecan (DS-6000) is an experimental anti-cancer treatment developed by Daiichi Sankyo and Merck. It is an antibody–drug conjugate that consists of a humanized IgG1 monoclonal antibody against the tumor-associated antigen cadherin-6 (CDH6), conjugated to deruxtecan (DXd), a cytotoxic DNA topoisomerase I inhibitor.